PubMed Health⌕ Search

Biomedical subjects

Timothy J Bosinski

Publications and source records attributed to Timothy J Bosinski.

3 recordsLinked to original sources

Recombinant factor VIIa, its clinical properties, and the tissue factor pathway of coagulation.

Recombinant factor VIIa (rFVIIa) is a synthetic coagulation protease that is structurally similar to human-derived plasma FVIIa. Pharmacologic doses of rFVIIa have been shown to enhance thrombin generation and assist in forming stable fibrin plugs at the site of injury. Recombinant factor VIIa appears to emerge as a valuable treatment alter-native for the treatment of bleeding episodes and for achieving hemostasis post surgery in those with bleeding disorders.

Blood Coagulation↗

Acute promyelocytic leukemia after iodine-131 therapy for Graves' disease.

Graves' disease is an autoimmune process in which the thyroid gland is stimulated by autoantibodies, leading to hyperthyroidism. Graves' disease is the most common cause of hyperthyroid function, primarily affecting women in their 40s and 50s. Treatment may involve oral radioiodine, which is taken up by the follicular cells of the thyroid, where it emits ionizing radiation to promote destruction of those cells. Radioiodine therapy is typically safe, effective, and inexpensive. We describe the case of a 51-year-old woman who developed acute promyelocytic leukemia within 27 months of completing a cumulative dose of radioiodine 22.1 mCi (817.7 MBq) for treatment of Graves' disease. Assessment of causality using the Naranjo probability scale showed that a possible relationship existed between this patient's acute promyelocytic leukemia and the use of radioiodine. Strict hematologic follow-up of patients treated with radioiodine may be warranted, along with a high index of suspicion in those with coagulopathy.

Female↗